Sugi Predict

Sugi Predict / Compounds / SCHEMBL21932018

SCHEMBL21932018

SCHEMBL21932018

CNCCOc1ccc(-c2cc(-c3c[nH]nc3-c3cccc(C)n3)ccn2)cc1

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ TGFBR1 P36897 18/20 0.41
▸ MAPK14 Q16539 6/20 0.41
▸ ACVR1B P36896 1/20 0.40
▸ KDR P35968 2/20 0.40
▸ RIPK2 O43353 1/20 0.39
▸ CDC7 O00311 1/20 0.35
▸ ROCK2 O75116 1/20 0.35
▸ MAP4K4 O95819 1/20 0.35
▸ PIM1 P11309 1/20 0.35
▸ PRKACA P17612 1/20 0.35
▸ CDK2 P24941 1/20 0.35
▸ GSK3B P49841 1/20 0.35
▸ HIPK2 Q9H2X6 1/20 0.35
▸ CLK4 Q9HAZ1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29528228 1.00 TGFBR1 (0.41) TGFBR1MAPK14ACVR1BKDRRIPK2
SCHEMBL22822809 0.92 TGFBR1 (0.40) TGFBR1MAPK14ACVR1BKDRCDC7
SCHEMBL21932036 0.88 TGFBR1 (0.49) TGFBR1ACVR1B
SCHEMBL29528202 0.88 TGFBR1 (0.49) TGFBR1ACVR1B
Hydrochloric Acid SCHEMBL21932094 0.87 TGFBR1 (0.48) TGFBR1ACVR1B
SCHEMBL5907484 0.85 TGFBR1 (0.50) TGFBR1MAPK14KDRRIPK2
SCHEMBL28539656 0.83 TGFBR1 (0.44) TGFBR1MAPK14ACVR1BKDRRIPK2
SCHEMBL21998930 0.83 TGFBR1 (0.48) TGFBR1ACVR1B
SCHEMBL31373673 0.83 TGFBR1 (0.40) TGFBR1MAPK14ACVR1BKDRRIPK2
SCHEMBL21375765 0.81 TGFBR1 (0.44) TGFBR1MAPK14KDRRIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230090552-A1 ALK5 INHIBITOR CONJUGATES AND USES THEREOF SYNTHIS THERAPEUTICS, INC. (US) 2023-03-23 — — US claimed
CN-115052663-A ALK5 inhibitor conjugates and uses thereof 辛瑟斯治疗股份有限公司 2022-09-13 — — CN claimed
US-20260049159-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES SYNTHIS THERAPEUTICS, INC. (US) 2026-02-19 — — US disclosed
US-12473377-B2 Antibody-ALK5 inhibitor conjugates and their uses SYNTHIS THERAPEUTICS, INC. (US) 2025-11-18 — — US disclosed
US-11987558-B1 ALK5 inhibitors and their uses SYNTHIS THERAPEUTICS, INC. (US) 2024-05-21 — — US disclosed
US-20230132568-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES SYNTHIS THERAPEUTICS, INC. (US) 2023-05-04 — — US disclosed
US-20230132568-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES SYNTHIS THERAPEUTICS, INC. (US) 2023-05-04 — — US disclosed
US-20230090552-A1 ALK5 INHIBITOR CONJUGATES AND USES THEREOF SYNTHIS THERAPEUTICS, INC. (US) 2023-03-23 — — US disclosed
US-20230090552-A1 ALK5 INHIBITOR CONJUGATES AND USES THEREOF SYNTHIS THERAPEUTICS, INC. (US) 2023-03-23 — — US disclosed
US-11583593-B2 Antibody-ALK5 inhibitor conjugates and their uses SYNTHIS THERAPEUTICS, INC. (US) 2023-02-21 — — US disclosed
US-11583593-B2 Antibody-ALK5 inhibitor conjugates and their uses SYNTHIS THERAPEUTICS, INC. (US) 2023-02-21 — — US disclosed
WO-2021142086-A1 ALK5 INHIBITOR CONJUGATES AND USES THEREOF SYNTHIS THERAPEUTICS, INC. (US) 2021-07-15 — — WO disclosed
EP-3820467-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES Synthis Therapeutics, Inc. (US) 2021-05-19 — — EP disclosed
CN-112601522-A antibody-ALK 5 inhibitor conjugates and uses thereof 辛瑟斯治疗股份有限公司 2021-04-02 — — CN disclosed
WO-2020256751-A1 ANTIB0DY-ALK5 INHIBITOR CONJUGATES AND THEIR USES SYNTHIS, LLC (US) 2020-12-24 — — WO disclosed
WO-2020256751-A1 ANTIB0DY-ALK5 INHIBITOR CONJUGATES AND THEIR USES SYNTHIS, LLC (US) 2020-12-24 — — WO disclosed
WO-2020256721-A1 ANTIB0DY-ALK5 INHIBITOR CONJUGATES AND THEIR USES SYNTHIS, LLC (US) 2020-12-24 — — WO disclosed
WO-2020256721-A1 ANTIB0DY-ALK5 INHIBITOR CONJUGATES AND THEIR USES SYNTHIS, LLC (US) 2020-12-24 — — WO disclosed
US-20200147234-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES SYNTHIS, LLC (US) 2020-05-14 — — US disclosed
US-20200147234-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES SYNTHIS, LLC (US) 2020-05-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12473377-B2 Antibody-ALK5 inhibitor conjugates and their uses ALK, ALKBH5, ALKBH3 TGFBR1 528/4885MAPK14 2643/4885ACVR1B 33/4885
US-11987558-B1 ALK5 inhibitors and their uses ALK, ALKBH3, ALKBH5 TGFBR1 106/4885MAPK14 1923/4885ACVR1B 9/4885
US-20230090552-A1 ALK5 INHIBITOR CONJUGATES AND USES THEREOF ALK, ALKBH5, ALKBH3 TGFBR1 75/4885MAPK14 1174/4885ACVR1B 24/4885
US-11583593-B2 Antibody-ALK5 inhibitor conjugates and their uses ALK, ALKBH5, ALKBH3 TGFBR1 528/4885MAPK14 2643/4885ACVR1B 33/4885
US-20260049159-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES ALK, CD2, TGFBR2 TGFBR1 5/4885MAPK14 1007/4885ACVR1B 12/4885
US-20200147234-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES ALK, ALKBH5, ALKBH3 TGFBR1 528/4885MAPK14 2643/4885ACVR1B 33/4885
US-20230132568-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES ALK, ALKBH5, ALKBH3 TGFBR1 528/4885MAPK14 2643/4885ACVR1B 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.